The Meliodays founding team: Benjamin Wolf, Simone Sabbione and Martin Sabbione (from left)
Photo: Meliodays Medical

Meliodays Medical: Hormone-free relief from menstrual pain

A hormone-free IUD for menstrual pain – doesn't exist yet? But soon! Meliodays Medical is developing MelioOne, an innovative, locally effective alternative to conventional painkillers. Simone Sabbione, CEO and co-founder, explains how the idea came about and where the startup aims to be in five years.

Munich Startup: What does Meliodays do? What problem does it solve?

Simone Sabbione, Meliodays Medical: We are developing the first hormone-free, locally acting treatment for menstrual pain.

Munich Startup: But that's been around for a long time!

Simone Sabbione: Actually, not. This was also confirmed by our comprehensive patent research in 2022. No one has ever investigated what happens when a classic painkiller like ibuprofen is injected directly into the uterus. This is precisely our approach: With MelioOne We are developing an IUD that releases a local painkiller instead of hormones.

“If men had menstrual pain, this would have been solved long ago.”

Munich Startup: What is your founding story?

Simone Sabbione:  I founded Meliodays together with my brother Benjamin and my husband Martin. For Martin, this is already his third startup, and Benjamin is a gynecologist. When I talked to him about menstrual pain, he said, "If men had menstrual pain, this would have been solved long ago." This sentence not only evoked anger in me, but also a strong motivation to create a better standard of care. This is how the idea for MelioOne was born.

Munich Startup: What have been your biggest challenges so far?

Simone Sabbione: The first and biggest challenge so far was convincing the first investors of our idea. After that, things became much easier – and finally, in early 2025, we were able to launch an oversubscribed Pre-Seed Round successfully complete.

Munich Startup: Where would you like to be in one year, where in five years?

Simone Sabbione: We aim to begin preclinical trials and complete our seed round in one year. In five years, following a successful market launch in the US, MelioOne aims to have received regulatory approval in Europe as well.

“You never feel alone”

Munich Startup: How have you experienced Munich as a startup location so far?

Simone Sabbione: Thanks to the high density of startup events and hubs, it's always possible to exchange ideas with other founders. This provides inspiration and support – especially on the not-so-easy path of starting a business. You never feel alone, and that helps enormously.

Munich Startup: Hidden champion or shooting star?

Simone Sabbione: Open Champion.

read more ↓